IBJNews

Lilly looks to autoimmune drugs

Back to TopCommentsE-mailPrintBookmark and Share

Two local researchers show why Eli Lilly and Co. and its peers are interested in developing medicines to treat autoimmune diseases: The costs of treating them are growing twice as fast as the prescription drug market.

Dr. Vivianne Beyer of St. Vincent Health and Dr. Stephen E. Wolverton of the Indiana University School of Medicine examined the trends for treating psoriasis in the January issue of the Archives of Dermatology, according to a story by BusinessWeek.

Psoriasis, a chronic autoimmune skin disease that affects 4.5 million to 7.5 million people, costs Americans more than $3 billion each year in medicines, doctors visits, lab tests and monitoring.

The average annual costs for brand-name psoriasis treatments rose by 66 percent from 2000 to 2008, Beyer and Wolverton found. Costs for all prescription drugs rose 31 percent over the same time period.

One driver of the increase has been new biotech drugs, which range in cost from $18,000 to $28,000 each year.

Autoimmune disease is one of three key focuses at Lilly’s biotech development hub in San Diego. Also, in December, Lilly paid $90 million to acquire the rights to an oral treatment for autoimmune diseases developed by Delaware-based Incyte Corp.

Other autoimmune diseases include rheumatoid arthritis, lupus and inflammatory bowel syndrome.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT